Trial Profile
A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa
- Indications Parkinson's disease
- Focus Adverse reactions
- Acronyms BeyoND
- Sponsors NeuroDerm
- 14 Mar 2024 According to a NeuroDerm media release, analyses of results from the ongoing BouNDless trial complement the long-term safety data from the BeyoND study (NCT02726386) including patients in their eighth year of follow-up.
- 05 Mar 2024 According to a Mitsubishi Tanabe Pharma America Media release, the company will present a posters in Parkinson's disease (PD) will be shared at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024), being held in Lisbon, Portugal, and virtually, from March 5-9
- 28 Aug 2023 According to a Mitsubishi Tanabe Pharma America Media release, results from this study will be shared at the International Congress of Parkinson's Disease and Movement Disorder Society (MDS), being held in Copenhagen, Denmark, August 27-31.